Steven Tee
Cardiovascular Disease · Hyattsville, MDNPI 1811980584
Payments from drug & device makers
Across 277 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$666
- Sanofi-aventis U.S. LLC$648
- Abbott$552
- Pfizer$476
- plus $4K from 30 others
What the payments were for
- Grants$451%
- Food & beverage$8,60598%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,357 |
| Novo Nordisk | 37 | $1,098 |
| Boehringer Ingelheim | 20 | $666 |
| Sanofi-aventis U.S. LLC | 18 | $648 |
| Abbott | 4 | $552 |
| Pfizer | 15 | $476 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $362 |
| Lilly USA, LLC | 11 | $331 |
| Gilead | 14 | $320 |
| AbbVie(2 entities) | 8 | $319 |
| Amgen | 8 | $293 |
| Johnson & Johnson | 8 | $279 |
| Novartis | 8 | $245 |
| Mylan Specialty L.p. | 8 | $228 |
| Merck | 9 | $203 |
| Actelion Pharmaceuticals US, Inc. | 5 | $177 |
| Boston Scientific | 4 | $156 |
| Biotronik Inc. | 2 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $128 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 5 | $92 |
| Hikma Pharmaceuticals USA | 4 | $70 |
| Arbor Pharmaceuticals, Inc. | 5 | $69 |
| Bayer | 3 | $68 |
| Amarin Pharma, Inc. | 4 | $65 |
| OPKO Pharmaceuticals, LLC | 2 | $43 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| Antares Pharma, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Sebela Pharmaceuticals Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| United Therapeutics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$594
- JARDIANCE$327
- CardioMEMS HF System$296
- Confirm Rx$256
- Truvada$245
- Xultophy 100/3.6$231
- Tresiba$218
- Ozempic$216
- PRALUENT$180
- ELIQUIS$130
- BRILINTA$126
- TRULANCE$125
- Yupelri$124
- ENTRESTO$122
- XARELTO$122
- VIBERZI$120
- Mavyret$119
- Repatha$117
- DISEASE STATE$116
- STEGLATRO$112
How this compares
$8,746 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Hyattsville
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Vineet VenugopalLanham$1.5M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.